PR View by Tom Jones

Nearly five years after the human genome was decoded, the age of genetics is finally upon us; “personalized medicine” has arrived. But this burgeoning field brings with it great uncertainties. Increasingly, drug and biotech companies develop targeted drugs that are effective for narrow populations, forcing an alternative to the traditional blockbuster, one-size-fits-all model.

This is not a challenge for drugmakers alone; those in public relations are also tasked with communicating to smaller, well-informed groups of patients. We live in an environment where it is easy for small groups of patients to find groups with similar interests online. As communicators, we must acknowledge this and push ourselves and clients to engage in these conversations.

Awareness: There are excellent tools to track patient conversations on blogs and elsewhere, and understanding who is having those discussions is the first step in personalized communication.

Appreciation: Online communities offer honesty and openness that outstrips the average focus group.

Engagement: Open and transparent participation in online conversations is the realization of this push toward personalized communications, building credibility with those groups.

This is not an approach that is without risks; biopharma faces unique requirements. But just as medicine is entering a new era, so must communications.

Tom Jones is managing director of Invigorate Communications
You must be a registered member of MMM to post a comment.

Content marketing is not advertising in the old sense. In its use of social media, content marketing challenges consumers while relying on their input. It is proactive and responsive to their concerns, needs and energy. Content marketing has become the new voice of marketing. Learn what you need to know and how pharma marketers can adapt to this innovative venture into social media by clicking here for access.

Email Newsletters